Over-expression of COX2 in the primary tumor was found to significantly attenuate splenic levels of Tregs by nearly 30% in mice challenged with TM40D-COX2 tumors, compared to mice with TM40D tumors (Figure 2C and D, p<0.05). This evidence concerns the gene PTGS2 and neoplasm.